Pinrid Tablet
NDC Package 73581-113-06
Package Information
Pinrid (pyrantel pamoate) tablets is important- treat the entire householddo not repeat treatment unless directed by a doctortake only one dose unless directed by doctorif signs of pinworms persist, see a doctorfor children less than 25 pounds or under 2 years old, consult a doctor before use.WeightDosage25-37 lb½ tablet38-62 lbs1 tablets63-87 lbs1½ tablets88-112 lbs2 tablets113-137 lbs2½ tablets138-162 lbs3 tablets163-187 lbs3½ tabletsover 188 lbs4 tablets . This formulation utilizes a tablet delivery system. Marketed by Yyba Corp, this product is identified by NDC 73581-113 and is authorized under FDA application M024.
Identification & Billing
- RxCUI: 668538 - pyrantel pamoate 720.5 MG (pyrantel 250 MG) Chewable Tablet
- RxCUI: 668538 - pyrantel pamoate 720.5 MG Chewable Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 73581 - Yyba Corp
- 73581-113 - Pinrid
- 73581-113-06 - 6 TABLET in 1 BOTTLE
- 73581-113 - Pinrid
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (73581-113). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 73581-113-06 identifies a specific commercial package of 6 tablet in 1 bottle of Pinrid, a human over the counter drug labeled by Yyba Corp. This tablet is formulated for oral use and contains pyrantel pamoate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Yyba Corp on October 01, 2025. The current certification is valid through December 31, 2027.
How is this Yyba Corp product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 73581011306. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.